Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

South Africa enters a new era in stroke prevention.

Aalbers J.

Cardiovasc J Afr. 2012 Nov;23(10):573. No abstract available.

2.

Anti-thrombotic trials in atrial fibrillation, the RELY study.

Aalbers J.

Cardiovasc J Afr. 2010 Sep-Oct;21(5):299. No abstract available.

3.

Focus on 2010 ESC Congress: new ESC guidelines and data on dabigatran.

Aalbers J.

Cardiovasc J Afr. 2010 Sep-Oct;21(5):300-1. No abstract available.

4.

Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.

Avecilla ST, Ferrell C, Chandler WL, Reyes M.

Am J Clin Pathol. 2012 Apr;137(4):572-4. doi: 10.1309/AJCPAU7OQM0SRPZQ.

PMID:
22431533
5.

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation.

Aalbers J, Bryer A, Klug E.

Cardiovasc J Afr. 2010 Nov-Dec;21(6):341. No abstract available.

6.

Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.

Wagenaar P.

Cardiovasc J Afr. 2011 Sep-Oct;22(5):283. No abstract available.

7.

Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.

Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS.

J Intern Med. 2012 Jan;271(1):15-24. doi: 10.1111/j.1365-2796.2011.02464.x. Epub 2011 Oct 31. Review.

8.

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.

Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8. Review.

PMID:
22318514
9.

[Chinese practical guide of dabigatran etexilate for stroke prevention in patients with non-valvular atrial fibrillation].

Working Group on Thrombosis of Chinese Journal of Cardiology.

Zhonghua Xin Xue Guan Bing Za Zhi. 2014 Mar;42(3):188-92. Chinese. No abstract available.

PMID:
24831473
10.

Initial experience with dabigatran etexilate at Auckland City Hospital.

Bell S, Nand J, Spriggs D, Young L, Dawes M.

N Z Med J. 2012 Feb 10;125(1349):105-7. No abstract available.

PMID:
22327149
11.
12.

Does dabigatran improve stroke prevention in atrial fibrillation? A rebuttal.

Stöllberger C, Finsterer J.

J Thromb Haemost. 2010 Jun;8(6):1436-7; author reply 1438-9. doi: 10.1111/j.1538-7836.2010.03738.x. Epub 2010 Jan 17. No abstract available.

13.

Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.

Eikelboom JW, Quinlan DJ, Connolly SJ, Hart RG, Yusuf S.

J Thromb Haemost. 2012 May;10(5):966-8. doi: 10.1111/j.1538-7836.2012.04668.x. No abstract available.

14.

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.

Ahmad Y, Lip GY.

Heart. 2012 Oct;98(19):1404-6. doi: 10.1136/heartjnl-2012-302101. Epub 2012 Jun 14. No abstract available.

PMID:
22698856
15.

New insights and results from the RE-LY trial.

[No authors listed]

Cardiovasc J Afr. 2011 Sep-Oct;22(5):284-6. No abstract available.

16.

[Stroke prevention in atrial fibrillation. Marcumar alternative in sight].

Einecke D.

MMW Fortschr Med. 2009 Sep 17;151(38):12-4. German. No abstract available.

PMID:
19831172
17.

Should dabigatran replace warfarin for stroke prevention in AF?

[No authors listed]

Drug Ther Bull. 2011 Oct;49(10):114-7. doi: 10.1136/dtb.2011.02.0060. Review.

PMID:
21994438
18.

[Still strong reason for enthusiasm for a new stroke-preventing drug].

Oldgren J.

Lakartidningen. 2009 Nov 4-12;106(45):3020-1. Swedish. No abstract available.

PMID:
19998832
19.

Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.

Khoo CW, Lip GY.

Expert Opin Pharmacother. 2010 Mar;11(4):685-7. doi: 10.1517/14656560903530691.

PMID:
20105114
20.

Dabigatran etexilate in people with atrial fibrillation.

Raju NC, Hankey GJ.

BMJ. 2010 Jul 29;341:c3784. doi: 10.1136/bmj.c3784. No abstract available.

PMID:
20671015

Supplemental Content

Support Center